Charles River Laboratories International company profile
Company profile
Charles River Laboratories International has 18,300 employees and is headquartered in Wilmington, United States.
With 18,300 employees, Charles River Laboratories International, Inc. runs drug discovery, non-clinical development and safety testing services for pharmaceutical and biotechnology companies and for researchers. Its research models unit breeds and sells purpose-bred rats and mice, along with genetically engineered models, insourcing solutions, research animal diagnostics and cell therapy development. Its discovery and safety assessment unit tests novel drugs, oligonucleotides, biotherapeutics and antibodies through toxicology, pathology, bioanalysis and pharmacokinetics work, plus vivarium space. The manufacturing solutions unit offers in vitro methods for rapid quality control of drugs and consumer goods, including sterile and non-sterile items, specialized biologics testing and contract development and manufacturing. Collaborations include the Parker Institute for Cancer Immunotherapy, Children's Hospital Los Angeles and Medigen Vaccine Biologics Corp. Revenue by region is 53.3% United States, 27.5% Europe, 12.5% Canada and 5.1% Asia Pacific.
In the fiscal year ended 27 December 2025, revenue was USD 4.0 billion, down 0.9% from the previous year, and the company reported a net loss of USD 144.3 million. Founded in 1947, it is headquartered in Wilmington, Massachusetts.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Headquarters
- 251 Ballardvale Street, 01887, Wilmington
- Employees
- 18,300
- Chief executive
- Birgit Girshick
- Founded
- 1947
- Fiscal year
- January - December
- Listing
- CRL · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US1598641074
- Website
- criver.com
Charles River Laboratories International and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Charles River Laboratories InternationalCRL | United States | $16.19B | 18,300 | 14.3% | 367.4 |
| RevvityRVTY | United States | $17.84B | 11,000 | 16.3% | 70.5 |
| ICON PublicICLR | United States | $14.58B | 40,250 | 2.7% | 77.9 |
| Medpace HoldingsMEDP | United States | $19.12B | 6,600 | 21.4% | 38.0 |
| Guardant HealthGH | United States | $20.52B | 2,490 | -39.4% | — |
| Quest DiagnosticsDGX | United States | $28.56B | 60,000 | 14.9% | 25.9 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
Compare Charles River Laboratories International with its competitors
